Angiotensin receptor blockers: Focus on cardiac and renal injury

被引:28
|
作者
Arumugam, Somasundaram [1 ]
Sreedhar, Remya [1 ]
Thandavarayan, Rajarajan A. [1 ,2 ]
Karuppagounder, Vengadeshprabhu [1 ]
Krishnamurthy, Prasanna [2 ]
Suzuki, Kenji [3 ]
Nakamura, Masahiko [4 ]
Watanabe, Kenichi [1 ]
机构
[1] Niigata Univ Pharm & Appl Life Sci, Dept Clin Pharmacol, Akiha Ku, Niigata, Japan
[2] Houston Methodist Res Inst, Dept Cardiovasc Sci, Houston, TX USA
[3] Niigata Univ, Grad Sch Med & Dent Sci, Dept Gastroenterol, Niigata, Japan
[4] Yamanashi Prefectural Cent Hosp, Dept Cardiol, Kofu, Yamanashi, Japan
基金
日本学术振兴会;
关键词
Renin angiotensin system; Angiotensin receptor blocker; Heart failure; Diabetes mellitus; Hypertension; HYPERTENSIVE PATIENTS; DIABETIC-NEPHROPATHY; AZILSARTAN MEDOXOMIL; CLINICAL-TRIAL; HEART-FAILURE; OLMESARTAN; ANTAGONIST; VALSARTAN; FIMASARTAN; IRBESARTAN;
D O I
10.1016/j.tcm.2015.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin II, an important component of renin angiotensin system, is a potent vasopressor and its actions are mostly mediated via angiotensin II type 1 receptor (AT(1)R) and role of AT(2)R in counterbalancing the actions of AT(1)R stimulation are under extensive research. In addition to its physiological actions, angiotensin II plays important roles in the pathogenesis of atherosclerosis, hypertension, left ventricular hypertrophy, and heart failure. The effects of angiotensin II can be blocked by either suppressing its production by blocking angiotensin converting enzyme or by antagonizing its actions on AT(1)R using angiotensin II receptor blockers (ARBs). Instead of the extensive use of ARBs in the treatment of various cardiovascular diseases, proper selection of a particular ARB is crucial as the clinical condition of individual patient is different and also their economic status would play an essential role in medication compliance. Thus a critical review of the proven and promising actions of ARBs against various pathological conditions will be of great importance for the clinicians as well as for the researchers.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 50 条
  • [1] Renal implications of angiotensin receptor blockers
    Hollenberg, NK
    AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (07) : 237S - 241S
  • [2] Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with Either Calcium Channel Blockers or Beta Blockers
    Farag, Selvia M.
    Rabea, Hoda M.
    Abdelrahim, Mohamed E. A.
    Mahmoud, Hesham B.
    CURRENT HYPERTENSION REVIEWS, 2022, 18 (02) : 138 - 144
  • [3] Combination Therapy in Hypertension: A Focus on Angiotensin Receptor Blockers and Calcium Channel Blockers
    Meka, Naga
    Katragadda, Srikanth
    Cherian, Biju
    Arora, Rohit R.
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (01) : 61 - 67
  • [4] Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
    Munger, M. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (07): : 93 - 104
  • [5] Comparative assessment of angiotensin receptor blockers in different clinical settings
    Verdecchia, Paolo
    Angeli, Fabio
    Repaci, Salvatore
    Mazzotta, Giovanni
    Gentile, Giorgio
    Reboldi, Gianpaolo
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 939 - 948
  • [6] Angiotensin Receptor Blockers - finally the evidence is coming in: IDNT and RENAAL
    Coats, AJS
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 79 (2-3) : 99 - 102
  • [7] Renal protection with angiotensin receptor blockers: where do we stand?
    Schmieder, Roland E.
    Ruilope, Luis-Miguel
    Barnett, Anthony H.
    JOURNAL OF NEPHROLOGY, 2011, 24 (05) : 569 - 580
  • [8] Efficacy of angiotensin receptor blockers in cardiovascular disease
    Maggioni, Aldo P.
    CARDIOVASCULAR DRUGS AND THERAPY, 2006, 20 (04) : 295 - 308
  • [9] Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
    Aldo P. Maggioni
    Cardiovascular Drugs and Therapy, 2006, 20 : 295 - 308
  • [10] Renal handling of angiotensin receptor blockers: Clinical relevance
    Domenic A. Sica
    Current Hypertension Reports, 2003, 5 : 337 - 339